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Objectives: Tostudy the clinical profile andmanagementof
Wegener’s granulomatosis (WG) with subglottic stenosis
(SGS) at a tertiary teaching hospital in Eastern India.
Methods: This prospective study incorporated a case se-
ries of six patients treated between 2007 and 2015 for WG
with SGS. The demographic details of the patients, such
as age, sex, clinical presentation, laryngeal endoscopy,
imaging, laboratory tests, and medical and surgical op-
tions, are described.
Results: Of the six patients, five had laryngeal symptoms,
such as hoarseness or breathing difficulty, at the time of
presentation. There were four female and two male pa-
tients ranging in age from 14 to 62 years. The diagnosis of
all six patients was confirmed via histopathological ex-
amination. Of the six patients, one had isolated subglottic
involvement, and four had a positive antineutrophilic
cytoplasmic autoantibody (C-ANCA) test on presenta-
tion. All of the patients received immunosuppressant and
steroid therapies at the time of diagnosis. Five patients
required tracheostomy with subglottic dilatation with
cold steel instruments followed by the local injection of
steroids and mitomycin-C application. Four patients
have shown clinical improvement.
Conclusion: Although WG is a rare clinical condition, it
is often confused with common ailments, which delays
diagnosis, and it may involve the subglottis. The sub-
glottis is a vital part of the laryngotracheal airway, and
mild obstruction can be life threatening. The accurate and
timely diagnosis of WG helps to prevent life-threatening
complications, such as SGS.his is an open access article under the CC BY-NC-ND license
16/j.jtumed.2016.01.005
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nd/4.0/).Figure 1: Nasopharyngolaryngoscopy showing subglottic stenosis.Introduction
Wegener’s granulomatosis (WG), or granulomatosis
with polyangitis (GPA), is an autoimmune multisystemic
inflammatory disease characterized by small- to medium-
vessel vasculitis with the formation of necrotizing granu-
lomas. Heinz Klinger first described WG in 1931; it was
subsequently described by Frederich Wegener in 1936.1
WG has a predilection for forming in the upper and
lower respiratory tract and kidneys. WG without kidney
involvement is referred to as limited Wegener’s. There is
no definitive cause of WG, although it is not infectious
or hereditary. The diverse clinical presentations of WG
contribute to difficulties in diagnosing this disease. WG
most commonly presents among patients in their sixth
and seventh decades of life, but it can occur at any age
and occurs with equal frequency between genders among
adults.2
Laryngotracheal involvement occurs in 16% cases of WG
and may be missed. Laryngotracheal involvement may be
symptom free, but its clinical manifestations can range from
subtle hoarseness to life-threatening stridor.3 Some cases
may present with normal chest X-rays. The narrowing of
the airway at the level of cricoid cartilage presents a
challenging situation for the treating doctors. WG is an
uncommon clinical condition, with a prevalence of 3 per
100,000; subglottic stenosis (SGS) occurs in approximately
16% of cases, leading to life-threatening airway obstruc-
tion.4 The characteristic laboratory findings in WG are
elevated ESR, leucocytosis, anaemia, elevated rheumatoid
factor and positive antiproteinase-3 ANCA. The C-ANCA
test is not always positive initially and should be repeated if
WG is suspected. SGS in WG usually does not respond to
medical treatment.5 We present a series of cases of WG with
SGS with an emphasis on early diagnosis and treatment.
Materials and Methods
All cases of WG with SGS were studied at a tertiary care
teaching hospital in eastern India between 2007 and 2015. All
of the six cases of WG were treated over eight years, and all
involved the subglottis. All were clinically assessed in an
attempt to further characterize this unusual disease entity
and to develop a rationale for the diagnosis and management
of the compromised laryngotracheal airway. To this end, the
existing literature on the subject was critically reviewed.
Case-1
A 21-year-old female was admitted with a history of
progressive breathing difficulty for 3 months. She hadundergone a tracheostomy for the sudden development of
respiratory failure on the ward. Nasopharyngolaryngoscopy
(NPL scopy) showed Grade II Cotton Meyer subglottic
stenosis (Figure 1), and the stenotic area had a concentric,
erythematous, friable appearance. Computed tomography
(CT scan) of the neck showed stenosis confined to the
subglottis, with no involvement other parts of the airway.
Laboratory tests showing elevated ESR, positive C-ANCA.
Microlaryngeal surgery (MLS) was performed under
general anaesthesia, and a biopsy of multiple fragments
from the subglottic lesion revealed granulation tissues.
Methyl prednisolone (80 mg) was injected at the stenotic
area, followed by dilation and the local application of
mitomycin-C (2 mg mitomycin-C diluted in 1 ml distilled
water). The chest X-ray was normal, but the paranasal sinus
(PNS) X-ray showed haziness in the right maxillary sinus. A
biopsy sample taken from the right maxillary sinus using an
endoscopic approach confirmed the WG diagnosis. Treat-
ment with glucocorticoids and cyclophosphamide was initi-
ated and lead to clinical improvement and the reduction of
SGS in the subsequent months.
Case-2
A 32-year-old man was referred for complaints of
hoarseness, coughing and difficulty breathing. Indirect
laryngoscopy showed narrowing of the subglottis with
circumferential boggy, erythematous folds of redundant tis-
sue. The vocal cords were normal and mobile. The results of
a general physical examination of the patient were within
normal limits. The blood counts and urine analysis were
normal. A Montoux test for tuberculosis was negative. A
chest X-ray showed a patch on one lobe; the PNS X-ray was
normal. A CT scan of the neck showed concentric narrow-
ing, with soft tissue confined to subglottis. Because of severe
subglottic obstruction and breathing difficulty, a tracheos-
tomy was performed and a biopsy was obtained. Histo-
pathological examination showed granulation tissue
infiltrated with lymphocytes, giant cells, histiocytes and a
small vessel in a non-inflamed area showing granulomatous
vasculitis (Figure 2). The subglottic area was injected with
Figure 2: Histopathology image showing granulations infiltrated
with lymphocytes, histiocytes, giant cells and a small vessel
showing granulomatous vasculitis. Figure 3: CT scan of the neck showing SGS.
Wegener’s granulomatosis causing subglottic stenosis 213steroids, and mitomycin-C was applied. The diagnosis of
WG was confirmed, and the patient was treated with pred-
nisolone 60 mg/day and cyclophosphamide 150 mg/day.
Subsequently, the subglottic airway showed improvement.
Case-3
A 14-year-old female known to have WG and undergoing
immunosuppressive therapy (prednisolone 60 mg/day and
cyclophosphamide 150 mg/day) was referred to us for
breathing difficulty with cough. She had undergone trache-
ostomy for stridor. She had a high ESR (110 mm/h), and her
C-ANCA was positive. Her chest X-ray showed patchy and
nodular areas with a ground glass appearance in both lung
fields, which were consistent with WG. Diagnostic nasal
endoscopy revealed crusts inside the nasal cavity, and an
earlier biopsy of the nasal cavity showed features of WG.
NPL scopy showed SGS. The CT scan of the neck confirmed
circumferential narrowing confined to the subglottis
(Figure 3). The patient was scheduled for MLS and dilation
with cold steel instruments. Methyl prednisolone (80 mg) was
injected at the stenotic area, followed by dilation and the
local application of mitomycin-C (2 mg mitomycin-C
diluted in 1 ml distilled water). After 3 months, the patient
tolerated the blocking of tracheostomy and subsequent
decannulation.
Case-4
A 27-year-old woman diagnosed with WG at an outside
institution was referred to us for mild dyspnoea at rest and a
brassy cough. NPL scopy showed SGS (Cotton-Myer Grade
III). A CT scan localized the lesion at the subglottis. In the
early stage, she was taking steroids and cyclophosphamide.
Her C-ANCA test was positive. A tracheostomy was per-
formed to treat stridor. Via MLS, the subglottic stenotic
segment was excised, and a local injection of steroids was
administered along with an application of mitomycin-C.
After 4 months, the tracheostomy tube was decannulated
and the subglottic area had improved.Case-5
A 62-year-old woman presented with nasal obstruction
and discharge. On examination, she presented mild dyspnoea
at rest and a brassy cough. The chest X-ray was normal.
Pulmonary function tests were consistent with extrathoracic
upper airway obstruction. NPL scopy showed sluggishly
moving bilateral vocal cords and a circumferentially nar-
rowed subglottic space (Cotton-Meyer Grade I). A biopsy of
the nasal granulomatous tissue showed typical necrotizing
WG. The patient’s C-ANCA test was positive. The patient
received prednisolone and cyclophosphamide, and no tra-
cheostomy was needed. The patient died one year after
treatment from renal failure.Case-6
A 55-year-old male with known WG and chronic renal
failure was referred to us for breathing difficulties, a hoarse
voice and nasal obstruction. NPL scopy showed Grade III
Cotton Meyer SGS. He was treated with prednisolone and
azathioprine. CT scan showed SGS. Tracheostomy was
performed for stridor. MLS with dilation of the subglottic
area, steroid injection and mitomycin-C application were
performed. The patient continued with azathioprine and
prednisolone. He is now under follow-up care.Results
All six cases of WG were referred to our department
within the last eight years. The diagnosis was confirmed via
histopathological examination. Four patients had a positive
C-ANCA test on presentation. Of the six patients, one had
isolated subglottic involvement. There were four female pa-
tients and twomale patients. The age range was from 14 to 62
years. Four patients had laryngeal symptoms at the time of
presentation and subsequently developed airway obstruc-
tion. The severity of SGS was determined according to the
patient’s history, clinical features, and laryngeal endoscopy
and imaging results. SGS in WG was diagnosed via NPL
S.K. Swain et al.214scopy and confirmed with radiological imaging of the lar-
yngotracheal airway. All of the patients had taken immu-
nosuppressants and steroids since the time of diagnosis. Of
the six patients, five required a tracheostomy. Via MLS, the
subglottic area was injected with methyl prednisolone, and
mitomycin-C was applied. Four patients improved with this
treatment; one patient is in follow-up, and one patient died of
renal failure. Details are provided in Table 1.
Discussion
WG is a rare autoimmune multisystemic disorder char-
acterized by granulomatous inflammation of the respiratory
tract, necrotizing vasculitis affecting small- to medium-sized
vessels, and necrotizing glomerulonephritis. WG is also
known as granulomatosis with polyangitis (GPA).5 Both
sexes are equally affected in WG; however, in our case
series, females outnumbered males (4:2).There are three
varieties of WG: Types 1, 2 and 3. Type 1 is the limited
form of WG, in which the patient presents with the
symptoms of upper respiratory infection for weeks and
does not respond to antibiotics. This type is associated
with serosanguinous nasal discharge, pain and crust
formation in the nasal cavities. In Type 2, in addition to
nasal involvement, other organs are involved. In Type 3
WG, there is widespread involvement of multiple organs,
including airway, pulmonary, renal and sometimes
dermatological lesions.6 Laryngotracheal manifestations in
WG are rare, with subglottic involvement being the most
common. Laryngeal manifestations occur as a late
complication of fully developed or previously treated WG.
They are seen in 8e23% of patients throughout the disease
process; they represent the first manifestation of WG in 1e
6% of cases7 and are common when WG is diagnosed
before the age of 20 years.8 Although all six patients in this
case series presented with SGS, in only one was the disease
confined to the subglottis. A few systemic diseases can
cause SGS, including WG, relapsing polychondritis,
sarcoidosis, and amyloidosis. Congenital stenosis, trauma
to the larynx, high tracheostomy and the extension of
tumours from another site to the subglottic area are otherTable 1: Detailed clinical profiles of the patients involved in this stud
SL No Gender Age
(years)
Clinical presentation Disease location S
t
1 Female 21 Breathing difficulty Subglottis, nose
and sinus
T
M
2 Male 32 Breathing difficulty
and hoarseness of voice
Subglottis, lungs T
M
3 Female 14 Breathing difficulty,
cough, nasal crusts
Subglottis, lungs,
sinus
T
M
4 Female 27 Breathing difficulty,
brassy cough
Subglottis T
M
5 Female 66 Pansinusitis, breathing
difficulty
Subglottis, sinus,
kidney
N
6 Male 55 Breathing difficulty,
nasal obstruction,
renal failure
Subglottis, nose,
kidney
T
Mcauses of SGS.9 The pathogenesis of SGS in WG is
unclear. It is thought that during systemic flare-ups, sub-
clinical subglottic involvement can occur, leading to healing
and circumferential scarring and stenosis. SGS can progress
even in the absence of systemic manifestations of WG. The
subglottis is a watershed area of microcirculation; therefore,
it is vulnerable to granulomatous inflammation. This
watershed area is the junction of two embryologically
different mucosal linings. The exposure of the respiratory
epithelium to gastric fluids during laryngopharyngeal reflux
is believed to play a role in the development of SGS. Initial
granulomatous inflammation at the subglottis leads to
circumferential scarring and narrowing of the airway.
The clinical presentations of WG are often heterogeneous
and often affect the upper respiratory tract, lungs, and kid-
neys. Localized forms of WG in the head and neck area are
not exceptional.10 The upper respiratory tract is affected in
95% of WG patients.9 The otolaryngological
manifestations of WG are sinusitis, nasal septal
perforation, saddle nose deformity, otitis media, hearing
loss and SGS (16%).Other clinical manifestations are
glomerulonephritis, pulmonary infiltrates, conjunctivitis,
scleritis, hyperthyroidism, arthralgia, neuropathy, and
pericarditis. In cases of WG with subglottic involvement,
dyspnoea on exertion is the most common clinical
manifestation; other symptoms include voice changes,
cough or stridor. SGS can be graded using the Cotton-
Myer classification, which considers circumferential nar-
rowing of the subglottic area: Grade I: Obstruction of 0e
50% of the lumen, Grade II: Obstruction of 51e70% of the
lumen, Grade III: Obstruction of 71e99% of the lumen, and
Grade IV: Obstruction of 100% of the lumen. The typical
history and classical clinical findings on examination of mild
to moderate anaemia and elevated ESR are suggestive of
WG.6 The diagnosis is confirmed via histopathological
examination. A positive C-ANCA test is an important
addition to the diagnosis of WG, but these autoantibodies
may be absent in certain cases, particularly in limited type
of the disease. ANCA are antibodies that target the two
important components of neutrophil granulocytes: PR3
serine and myeloperoxidase. Anti-PR3 antibodies arey.
urgical
reatment
Immunosuppressive therapy Outcome
racheostomy,
LS
Prednisolone and
cyclophosphamide
Improved
racheostomy,
LS
Prednisolone, cyclophosphamide,
tracheostomy
Improved
racheostomy,
LS
Prednisolone, cyclophosphamide,
MLS with dilation with cold steel
instruments
Improved
racheostomy,
LS
Prednisolone, cyclophosphamide,
tracheostomy
Improved
ot applicable Prednisolone, cyclophosphamide Patient died of
renal failure
racheostomy,
LS
Azathioprine, prednisolone,
tracheostomy
Patient with
tracheostomy;
undergoing
follow-up
Wegener’s granulomatosis causing subglottic stenosis 215virtually pathognomonic of WG, whereas anti-
myeloperoxidase antibodies are more consistent with
necrotizing primary vasculitis, as seen in microscopic poly-
angitis.11 There are two types of tests to detect ANCA:
Immunofluorescence or enzyme linked immunoassay
(ELISA). The immunofluorescence test differentiates
between anti-PR3 and anti-myeloperoxidase on the basis of
staining patterns: the first is associated with C-ANCA, and
the second is associated with P-ANCA.12 Detection with
ELISA (the presence of anti-PR3 or anti-myeloperoxidase)
offers greater specificity. When both techniques are com-
bined, the sensitivity and specificity for the diagnosis of WG
increase to 90% and 98%, respectively.13 The sensitivity of
the C-ANCA test was found to be 67% with
immunofluorescence and 60% with ELISA for patients
with active local or regional symptomatology.14 A negative
C-ANCA test does not exclude the diagnosis of WG. The
sensitivity of the ANCA test depends on the extent of the
lesions and activity at the time of the test. In our series, C-
ANCA was positive in four patients at the time of
presentation, whereas the other two cases became positive
later in the course of the disease. C-ANCA is not constant
throughout the course of the disease and can be modified
with medical treatment.
Biopsies give best information for diagnosis. Subglottic
biopsies are not always sensitive as large amounts of tissue
from the subglottic area are difficult to obtain. The diagnosis
of WG is confirmed with a biopsy that shows necrotizing
granulomatous vasculitis.9 Biopsies from pulmonary lesions
provide the highest diagnostic yield, but biopsies from other
parts, such as the airway and kidney, can also be taken for
diagnosis.9 The classical laboratory findings are markedly
elevated ESR, anaemia, leucocytosis, elevated rheumatoid
factor and positive antiproteinase-3 ANCA.9
The head and neck manifestations of patients with WG
usually respond well to immunosuppressive therapy (cyclo-
phosphamide or methotrexate) along with glucocorticoids
for several months during the active phases of the disease.
Later, the patient will require maintenance therapy with
azathioprine and methotrexate during the quiescent phase,
along with boluses of glucocorticoids to control the reac-
tivation of the diseases.15 Monoclonal antibodies against
CD20 (rituximab) can also useful in WG.16 During the
early stage of laryngotracheal involvement of WG,
corticosteroids and cyclophosphamide are used, but only
20% of cases respond. All of our cases received
immunosuppressive therapy, but there was no long-lasting
benefit to the course of the SGS in any of the cases. This
suggests that SGS can occur independent of the systemic
manifestations and their treatment. Intralesional steroids
have been used to treat SGS and have been shown to reduce
the need for systemic therapy. Intralesional corticosteroids
are a safe and effective treatment when used in conjunction
with dilation of the SGS. Intralesional steroid injection and
the application of mitomycin-C was performed in five out of
the six cases. SGS can be treated with airway dilation via
silicon or metal stent placement, but the prognosis remains
guarded.17 In cases of resistant fixed obstructions of the
airway, open reconstructive surgery, such as laryngoplasty
and cricotracheal resection with primary stenosis, is
useful.17 CO2 laser treatment of SGS has been attempted
but has not proven useful in extensive cases.Conclusion
AlthoughWG is a rare clinical condition, an accurate and
timely diagnosis can be made on the basis of certain clinical
features and laboratory tests and confirmed with biopsy.
Because airway involvement may occur in WG, it is essential
that the treating physicians rule out this condition; as
favourable diagnosis depends on early detection and treat-
ment. Microlaryngoscopy and dilation with mitomycin-C
and steroid treatments provide good results in cases of
SGS caused by WG. A combination of clinical features,
immunological tests and characteristic histopathological
presentation are needed to establish the diagnosis. A CT scan
is performed to define the extent of the stenosis. Patients who
do not respond to immunosuppressive therapy may require
surgical intervention. In our series, four patients improved,
one patient is in follow-up, and one patient died from renal
failure The treating physicians should always aware of the
possibility of SGS in WG, which may lead to life-threatening
stridor.
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